Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Neuraxis, INC

Get SEC filing alerts via email and in your feed for Neuraxis, INC

NRXS

Neuraxis, INC

About Neuraxis, INC

Neuraxis, Inc. develops neuromodulation medical devices targeting pediatric and adult gastrointestinal and neurological conditions. Its core products include FDA-cleared non-invasive nerve stimulation systems for functional abdominal pain, IBS, and related disorders. The company leverages proprietary patents, clinical research, and strategic licensing to provide evidence-based, non-drug therapies that improve patient outcomes, primarily serving hospitals, clinics, and healthcare providers in the US and globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Neuraxis, INC

1
1
Neuraxis, INC NeurAxis Reports 79.5% Revenue Growth to $1.6 Million in Latest Quarter

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Neuraxis, INC Neuraxis Reports $7.8 Million Net Loss, 32.9% Revenue Growth in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Neuraxis, INC NeurAxis Reports Q3 2025 Financial Results with Increased Revenue and Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Neuraxis, INC NeurAxis Reports 46.2% Revenue Growth but Faces Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Neuraxis, INC NeurAxis Reports Q1 2025 Financial Results with Increased Revenue but Higher Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Neuraxis, INC Neuraxis Reports $8.2 Million Net Loss, Revenue Increases by 9.2% in Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Neuraxis, INC NeurAxis Reports 39.6% Revenue Growth, Mixed Financial Results in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments